P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE. (23rd June 2022)

• Record Type: Journal Article
• Authors: Bücklein, V.; Perez, A.; Iacoboni, G.; Rejeski, K.; Holtick, U.; Penack, O.; Kharboutli, S.; Blumenberg, V.; Ackermann, J.; Frölich, L.; Johnson, G.; Patel, K.; Arciola, B.; Schmidt, C.; Albanyan, O.; Gödel, P.; Hoster, E.; Bullinger, L.; Mackensen, A.; Locke, F.; von Bergwelt, M.; Barba, P.; Jain, M. D.; Subklewe, M.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 1330
• Page End: 1331
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000848644.19354.c7
• Languages: English
• ISSNs: 2572-9241